US · Healthcare · Medical Instruments & Supplies
EPS came in at 2.37 against a street estimate of 2.08 — a beat of 13.9%.
Analysts rate West Pharmaceutical Services Inc a strong buy (12 buy, 1 hold, 0 sell out of 13) with an average price target of $404.73.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.71% |
| Vanguard Capital Management, LLC | 6.65% |
| Vanguard Portfolio Management, LLC | 5.82% |
| State Street Corp | 4.68% |
| Artisan Partners Limited Partnership | 3.78% |
| Bank of New York Mellon Corp | 3.50% |
| T. Rowe Price Investment Management,Inc. | 3.33% |
| Generation Investment Management LLP | 3.19% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-23 |
| Results announced · Q3 2026 | 2026-07-23 |
| Material agreement · Q3 2026 | 2026-07-14 |
| Board / officer change · Q2 2026 | 2026-06-01 |
| Reg FD disclosure · Q2 2026 | 2026-05-11 |
| Quarterly report · Q1 2026 | 2026-04-23 |
| Proxy statement · Q2 2026 | 2026-03-12 |
| Annual report FY2025 | 2026-02-17 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for West Pharmaceutical Services Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.